Abstract
The Workshop associated with the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), North Bethesda, MD, October 24-25, 2012 focused on targeting the tumor microenvironment as part of an integrative approach to immune-based cancer therapy.
Highlights
The Workshop associated with the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), North Bethesda, MD, October 24-25, 2012 focused on targeting the tumor microenvironment as part of an integrative approach to immune-based cancer therapy
The Society for Immunotherapy of Cancer (SITC) held a workshop focused on targeting the tumor microenvironment as part of an integrative approach to immune-based cancer therapy
The following themes were selected for the focus of the 2012 SITC workshop: (1) cellular and molecular interactions within the tumor microenvironment that impact the activities of innate and antigen-specific immune cells; (2) manipulation of these interactions to remodel the tumor microenvironment and promote tumor regression (3) current and future combination cancer immunotherapies for clinical use that actively target components of the tumor microenvironment to provoke lasting tumor immunity and improve patient outcomes; and (4) the tumor Immunoscore as a new indicator of prognosis, and predictive marker of response to cancer therapy
Summary
The research presented at the 2012 SITC Workshop highlighted a rapidly growing appreciation for the complexities of the tumor microenvironment, and how they might be manipulated therapeutically to promote or even provoke effective tumor immunity. Accurately profiling the immunobiology of the tumor microenvironment—and standardizing an Immunoscore—will better define prognosis and response to both immune-based and standard cancer therapies. The future of immunotherapy will almost certainly involve integrative strategies that target multiple immune modulating networks and effector cells to to amplify existing immune responses in patients predicted to be immunologic responders, and to stimulate new immunity that can be subsequently amplified in patients predicted to be immunologic nonresponders. Sequential combination treatment strategies matched to both the genetics and immunobiology of a patient’s tumor will make personalized immunotherapy a reality, leading to increased cancer cure rates and effective cancer prevention strategies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
